Cencora, Inc. · NYSE:COR
Cencora — Q3 2023 Earnings Presentation
18 slides from Cencora's earnings presentation, Aug 2, 2023
Slide 1: Q3 FY2023 Financial Results
Q3 FY2023 Financial Results August 2, 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: United in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health as a leading provider of pharmaceutical distribution services and differentiated value-added solutions for upstream an
Slide 4: Overview
Overview Recent highlights Global healthcare leader Fiscal 2023 guidance • Announced the close of • Foundation of leadership • Updated fiscal 2023 OneOncology, a minority in pharmaceutical guidance primarily investment which will distribution reflects strong deepen relationships • Complementary high
Slide 5: Q3 FY2023 financial results: consolidated
Q3 FY2023 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $66.9B $66.9B % Change (Year-over-Year) 11.5% 11.5% Gross profit $2.3B $2.2B % Change 12.4% 8.0% Operating expenses $1.6B $1.4B % Change 4.3% 7.6% Operating income $670M $822M % Change 37.5% 8.7% Interest expense, net
Slide 6: U.S. Healthcare Solutions segment
Q3 FY2023 financial results U.S. Healthcare Solutions segment Q3 FY2023 Q3 FY2022 YoY Change Revenue $59.9B $53.4B 12.2% Operating income $635M $580M 9.5% Percentages of revenue Gross profit 2.36% 2.49% Operating expenses 1.29% 1.40% Operating income 1.06% 1.09% • Revenue increase of 12.2% due to ov
Slide 7: International Healthcare Solutions segment
Q3 FY2023 financial results International Healthcare Solutions segment Q3 FY2023 Q3 FY2022 YoY Change Revenue, as reported $7.0B $6.7B 5.6% Revenue, constant currency1 12.4% Operating income, as reported $187M $176M 6.2% Operating Income, constant currency1 7.3% Percentages of revenue, as reported G
Slide 8: Consolidated FY2023 guidance
Consolidated FY2023 guidance Updated guidance primarily reflects strong performance to date and updated FX translation rates As reported Constant currency1 As reported Constant excluding currency1 COVID-19 excluding COVID contributions Revenue At least 8% At least 9% Adjusted operating income1 3% to
Slide 9: Segment level FY2023 guidance
Segment level FY2023 guidance Updated guidance primarily reflects strong performance to date and updated FX translation rates U.S. Healthcare Solutions As reported Excluding COVID-19 contributions Revenue At least 9% Adjusted operating income1 4% to 5% 7% to 8% International Healthcare As reported C
Slide 10: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist Our 5 Strategic Imperatives We are united in our responsibility to create healthier futures Our areas of focus Advance core bu
Slide 11: Advancing environmental, social, and governance initiatives
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and communities • Near-term Science-Based Target validated by • Launched a Global Inclusion Index to measure the Scienc
Slide 12: Appendix
AmerisourceBergen Appendix
Slide 13: GAAP to Non-GAAP Reconciliations, Three Months Ended June 30, 2023
AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended June 30, 2023 Net Loss (Income) Income Attributable to Net Income Diluted Operating Operating Before Income Tax Noncontrolling Attributable Earnings Gross Profit Expens
Slide 14: GAAP to Non-GAAP Reconciliations, Three Months Ended June 30, 2022
AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended June 30, 2022 Net Loss Income (Income) Before Attributable to Net Income Diluted Operating Operating Income Income Tax Noncontrolling Attributable Earnings Gross Profit
Slide 15: Supplemental Measures
Supplemental Information Regarding Non-GAAP Financial Measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 16: Supplemental Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted income before income taxes: Adjusted income before income taxes is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted operating income. In addition, the recove
Slide 17: Supplemental Measures (Cont.)
Supplemental Information Regarding Non-GAAP Financial Measures (Cont.) • Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credi
Slide 18: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury bmurphy@amerisourcebergen.com